<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01181427</url>
  </required_header>
  <id_info>
    <org_study_id>M12-116</org_study_id>
    <nct_id>NCT01181427</nct_id>
  </id_info>
  <brief_title>Study of ABT-267 in Both Healthy Volunteers and Hepatitis C Virus (HCV) Genotype 1 Infected Subjects</brief_title>
  <official_title>A Blinded, Randomized, Placebo-Controlled Study in Healthy and HCV Genotype 1-infected Adults, to Evaluate the Safety, Tolerability, Antiviral Activity, Pharmacokinetics (Including the Effect of Food) and Resistance Profile of Single and Multiple Doses of ABT-267</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of ABT-267 in both healthy volunteers and Hepatitis C virus (HCV) genotype 1 infected
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of pharmacokinetic variables and mean change in HCV RNA level from baseline.</measure>
    <time_frame>Up to 15 days or less</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of safety measures including but not limited to tabulation of adverse events, physical exam, vital signs, ECGs, continuous cardiac monitoring, and clinical lab results (including chemistry, hematology and urine).</measure>
    <time_frame>Update to 20 days or less</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">137</enrollment>
  <condition>HCV Infection</condition>
  <arm_group>
    <arm_group_label>Single Ascending Dose (SAD)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy volunteers, receiving single ascending doses of ABT-267 or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose (MAD)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy volunteers, receiving multiple ascending doses of ABT-267 or placebo, OR, multiple doses of ABT-267 + single dose of a Cytochrome P450 inhibitor or placebo + single dose of a Cytochrome P450 inhibitor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Food Effect (FE)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy volunteers, receiving ABT-267, multi-dose, food effect.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antiviral Activity</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>HCV genotype 1-infected treatment naïve subjects receiving multiple ascending doses of ABT-267 or placebo monotherapy for 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Resistance Monitoring</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>HCV genotype 1-infected treatment naïve subjects, receiving at least one dose of ABT-267 or placebo in the &quot;Antiviral Activity&quot; arm, follow-up to monitor resistance developed to ABT-267, no treatment and only blood samples will be collected</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-267</intervention_name>
    <description>See arm description</description>
    <arm_group_label>Single Ascending Dose (SAD)</arm_group_label>
    <arm_group_label>Multiple Ascending Dose (MAD)</arm_group_label>
    <arm_group_label>Food Effect (FE)</arm_group_label>
    <arm_group_label>Antiviral Activity</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>See arms description</description>
    <arm_group_label>Single Ascending Dose (SAD)</arm_group_label>
    <arm_group_label>Multiple Ascending Dose (MAD)</arm_group_label>
    <arm_group_label>Antiviral Activity</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood Sample Collection</intervention_name>
    <description>See arm description</description>
    <arm_group_label>Resistance Monitoring</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytochrome P450 inhibitor</intervention_name>
    <description>See arm description</description>
    <arm_group_label>Multiple Ascending Dose (MAD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Main Selection Criteria for Healthy Volunteers:

          -  Subject has provided written consent.

          -  Subject is in general good health.

          -  Females must be post-menopausal for at least 2 years or surgically sterile.

          -  Females must not be pregnant or breast-feeding. If male, subject is surgically sterile
             or practicing specific forms of birth control.

        Main Selection Criteria for HCV Genotype 1-infected Volunteers:

          -  Subject has provided written consent.

          -  Subject has chronic HCV genotype 1 infection at screening.

          -  Liver biopsy within 3 years with histology.

          -  Females must be post-menopausal for at least 2 years or surgically sterile.

          -  Females must not be pregnant or breast-feeding. If male, subject is surgically sterile
             or practicing specific forms of birth control.

          -  Subject is in general good health, as perceived by the investigator, other than HCV
             infection.

        Main Selection Criteria for Volunteers in the Resistance Monitoring Portion of the Study:

          -  Subject has provided written consent, has received at least one dose of ABT-267 or
             placebo in the study, and is considered suitable by the investigator to participate.

        Exclusion Criteria

        Main Exclusion Criteria for Healthy Volunteers:

          -  Positive test for HAV IgM, HBsAg, HCV Ab or HIV Ab.

          -  Clinically significant cardiovascular, respiratory (except mild asthma), renal,
             gastrointestinal, hematologic, neurologic, thyroid, or any uncontrolled medical
             illness or psychiatric disorder.

          -  Use of tobacco or nicotine-containing products with the 6-month period prior to study
             drug administration.

          -  Abnormal screening laboratory results.

          -  Significant sensitivity to any drug.

          -  Requirement for any over the counter and/or prescription medication, vitamins and/or
             herbal supplements on a regular basis.

        Main Exclusion Criteria for HCV Genotype 1-infected Volunteers:

          -  Significant sensitivity to any drug.

          -  Positive HBsAg, HAV-IgM, and HIV Ab. Use of CYP enzyme inducers or inhibitors within 1
             month of dosing.

          -  Clinically significant cardiovascular, respiratory (except mild asthma), renal,
             gastrointestinal, hematologic, neurologic, thyroid disease (except hypothyroidism on
             stable thyroid replacement therapy), or any uncontrolled medical illness or
             psychiatric disorder.

          -  Use of any medications (prescription and over-the counter) within 2 weeks prior to
             study drug dosing without prior approval by the Abbott Medical Monitor.

          -  Use of any vitamins or herbal supplements within 2 weeks prior to study drug dosing.

          -  Prior treatment with any investigational or commercially available anti-HCV agents.

          -  Abnormal screening laboratory results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Campbell, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 42708</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43322</name>
      <address>
        <city>Waukegan</city>
        <state>Illinois</state>
        <zip>60085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 42707</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2010</study_first_submitted>
  <study_first_submitted_qc>August 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2010</study_first_posted>
  <last_update_submitted>January 20, 2012</last_update_submitted>
  <last_update_submitted_qc>January 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
    <mesh_term>Cytochrome P-450 Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

